[Local treatment with tumor necrosis factor alpha in a patient with lung cancer].
Tumor Necrosis Factor alfa (TNFa) is a cytokine with cytolytic and cytotoxic properties. First clinical trials in which TNF was administered parenterally date back to early 70-ties. Soon it was noticed that when administered strictly to the tumor mass TNF exhibits high anti-tumor efficacy, exemplified by total or at least substantial regression of the tumor mass while producing minor and controllable symptoms. In this paper the case of local administration of the recombinant TNFa directly into the tumor mass constricting the bronchus was presented.
Chciałowski
A
A
Kliniki Chorób Wewnetrznych i Pneumonologii Instytutu Medycyny Wewnetrznej, Centralnego Szpitala Klinicznego WAM w Warszawie.
Płusa
T
T
Szczylik
C
C
Mamełka
B
B
Bajera
I
I
Targowski
T
T
Dudko
S
S
Wcisło
G
G
D000328:Adult; D010478:Chemotherapy, Cancer, Regional Perfusion; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D012074:Remission Induction; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage*
D014409:Tumor Necrosis Factor-alpha